Company:PaxVax
| Type | Private |
|---|---|
| Industry | Vaccines |
| Founded | 2006 |
| Headquarters | Redwood City, California, United States |
Key people | Nima Farzan (CEO) |
| Website | PaxVax.com |
PaxVax Corporation researches, develops, manufactures, and commercializes vaccines against various infectious diseases. PaxVax manufactures the typhoid vaccine Vivotif and cholera vaccine Vaxchora.[1][2]
In 2014, PaxVax partnered with Spector Lab at the UC San Diego Department of Cellular and Molecular Medicine to develop a genital herpes viral vector vaccine. The vaccine was in the pre-clinical stage.[3] The project has likely been discontinued.
In May 2018, PaxVax received fast track designation from the FDA for its chikungunya vaccine, which is currently in phase 2 testing.[4]
PaxVax was the subject of a hoax, widely reported by anti-vaccination media, claiming that Australia was forcibly vaccinating its citizens by aerial spraying.[5]
In August 2018, it was announced that PaxVax would be acquired by Emergent BioSolutions for $270 million.[6] The takeover was completed in October 2018.[7]
References
- ↑ "Company Overview of PaxVax Corporation". https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=35290325. "PaxVax Corporation researches, develops, manufactures, and commercializes vaccines against various infectious diseases. Its products include PXVX0200, a single-dose oral vaccine against cholera; Vivotif, a typhoid fever vaccine for oral administration; Epaxal, a vaccine for hepatitis A; PXVX0103, an oral adenoviral-based vaccine against avian influenza (H5N1) or bird flu; a single-dose oral vaccine candidate for protection against anthrax; Ad4-env Clade C, a HIV vaccine component that expresses an optimized HIV envelope protein derived from a Clade C HIV strain; and Ad4-mGag, a HIV vaccine component that expresses an optimized HIV gag protein. The company also engages in the research and development of vaccines against malaria, dengue, rabies, and herpes simplex virus. It offers vaccines for travelers and biodefense in the United States and internationally. PaxVax Corporation was founded in 2006 and is based in Redwood City, California. It has research and development and good manufacturing practice facilities in San Diego, California; and Thörishaus, Switzerland."
- ↑ Carroll, John (28 July 2014). "PaxVax nails down $62M to complete vaccine buyout, PhIII study". https://www.fiercebiotech.com/r-d/paxvax-nails-down-62m-to-complete-vaccine-buyout-phiii-study.
- ↑ "PaxVax Signs R&D Collaboration with UC San Diego to Develop a Vaccine to Prevent Herpes Simplex Virus Infections - PaxVax - Socially Responsible Vaccines". 10 June 2014. http://paxvax.com/about/news/paxvax-signs-rd-collaboration-uc-san-diego-develop-vaccine-prevent-herpes-simplex-virus.
- ↑ Rosa, Kristi (7 May 2018). "PaxVax Chikungunya Vaccine Granted Fast Track Designation by FDA". http://www.contagionlive.com/news/paxvax-chikungunya-vaccine-granted-fast-track-designation-by-fda.
- ↑ "Is Australia Using Chemtrails to Forcibly Vaccinate its Residents?". Snopes. 25 January 2018. https://www.snopes.com/fact-check/is-australia-chemtrails-vaccinate-residents/.
- ↑ Gregg, Aaron (12 August 2018). "Emergent BioSolutions to acquire cholera and typhoid vaccines in $270 million deal". Washington Post. https://www.washingtonpost.com/business/capitalbusiness/emergent-biosolutions-to-acquire-cholera-and-typhoid-vaccines-in-270-million-deal/2018/08/12/6f7165b6-9be1-11e8-8d5e-c6c594024954_story.html.
- ↑ "Emergent BioSolutions Completes Acquisition of Specialty Vaccines Company PaxVax NYSE:EBS". 4 October 2018. https://www.globenewswire.com/news-release/2018/10/04/1617201/0/en/Emergent-BioSolutions-Completes-Acquisition-of-Specialty-Vaccines-Company-PaxVax.html.
External links
 |
